Most large, long-term studies find that IVF injections do not cause severe lasting health consequences for the majority of women who undergo treatment. The hormones used in ovarian stimulation temporarily push the body into a state it was never designed for, producing far more eggs than a natural cycle would, and the short-term effects of that process can be intense. But the question people really want answered is whether those drugs leave a mark years or decades later. The evidence is more reassuring than many expect on some fronts, like cancer, and more complicated than commonly discussed on others, like cardiovascular health and mental well-being.
Cancer Risk After IVF
The hormone injections used in IVF, particularly gonadotropins and sometimes clomiphene, push estrogen levels far above their natural range during a stimulation cycle. Because estrogen exposure is a known risk factor for certain cancers, women understandably worry about what repeated cycles might mean for their long-term cancer risk. Some researchers have raised concerns that long-term use of IVF medications could increase estrogen-driven gene expression and theoretically raise breast cancer risk.1PubMed Central. In-Vitro Fertilization Impact on the Risk of Breast Cancer: A Review Article But the largest and most rigorous studies tell a different story.
A major Dutch cohort study that followed over 25,000 women for more than two decades found that breast cancer risk in IVF-treated women was essentially the same as in the general population. The cumulative incidence of breast cancer by age 55 was about 3.0% in the IVF group and 2.9% in the comparison group, a difference so small it was statistically meaningless.2JAMA. Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer That finding has been replicated in other large population studies and is now the mainstream conclusion in reproductive medicine: IVF does not appear to raise breast cancer risk.
The picture for endometrial cancer is similar. While a handful of individual studies have flagged modest increases, a meta-analysis covering more than 776,000 patients found no increased risk of endometrial cancer in women who had undergone fertility treatment compared to those who had not.3PubMed Central. Use of fertility medications and cancer risk: A review and update
Melanoma is where the data gets slightly more ambiguous. A large Danish population-based study found that women who had used fertility drugs had a modestly increased risk of melanoma compared to fertile women, with a hazard ratio of about 1.14. When the researchers broke down the results by specific drug types, including gonadotropins and progesterone, the individual associations were smaller and did not reach the threshold for statistical significance.4PubMed. Use of Fertility Drugs and Risk of Malignant Melanoma: Results from a Large Danish Population-Based Cohort Study Other studies have not found a clear link at all, leaving researchers debating whether IVF itself contributes to melanoma risk or whether infertility and the hormonal profile of women seeking IVF are the real factors at play.5PubMed Central. Melanoma Following In Vitro Fertilization: Co-incident or Coincidence? This distinction matters: many women who use IVF have underlying hormonal conditions, like polycystic ovary syndrome, that could independently affect cancer risk. Separating the drug effect from the patient-profile effect is one of the hardest problems in this field.
Cardiovascular and Metabolic Effects
This is an area where the research is thinner but the signal is worth paying attention to. A survey-based study of women who underwent fertility treatments found that roughly one in seven reported developing cardiovascular disease, and a similar proportion reported metabolic disorders. Among the IVF subgroup specifically, about 13.6% had cardiovascular disease and about 18.5% had metabolic disorders.6PubMed Central. Long-Term Effects of Fertility Treatments on Maternal Health Those rates are hard to interpret in isolation because the study did not compare against a perfectly matched control group. Women seeking IVF tend to be older at the time of pregnancy, are more likely to have conditions like PCOS that carry their own metabolic risk, and may have pregnancies complicated by factors (like multiples) that strain the cardiovascular system. Still, the numbers suggest this is an area that deserves more attention than it gets.
Gestational diabetes during an IVF pregnancy is a more concrete finding. A nationwide register-based cohort study in Finland found that pregnancies conceived through IVF had higher rates of gestational diabetes than naturally conceived pregnancies, roughly 31% versus 26%. After adjusting for maternal age, body mass index, and other factors, IVF pregnancies still carried about 26% higher odds of gestational diabetes.7PubMed Central. In vitro fertilization increases the odds of gestational diabetes: a nationwide register-based cohort study Gestational diabetes itself resolves after delivery, but women who develop it face a substantially higher lifetime risk of developing type 2 diabetes later. So the connection between IVF and gestational diabetes could, indirectly, become a long-term metabolic concern.
Blood Clots and Ovarian Hyperstimulation
Ovarian hyperstimulation syndrome, or OHSS, is the most well-known acute complication of the injectable hormones used in IVF. In its severe form, the ovaries swell dramatically and fluid leaks from blood vessels into the abdomen and sometimes the chest, causing bloating, pain, nausea, and in rare cases dangerous drops in blood volume.8PubMed Central. Ovarian hyperstimulation syndrome Mild OHSS is common and self-resolving, but severe cases can require hospitalization and carry real risks.
One of those risks is blood clots. The combination of high estrogen levels, the hypercoagulable state that pregnancy itself creates, and the fluid shifts from OHSS can set the stage for deep vein thrombosis. Case reports have documented DVT developing during early IVF pregnancies, sometimes requiring treatment with blood thinners throughout the pregnancy.9PubMed Central. Deep venous thrombosis in a patient undergoing In-vitro fertilization with oocyte donation The risk is highest in the first trimester and in women who had OHSS, but it is not exclusively limited to severe cases. Women with a personal or family history of clotting disorders should discuss this with their fertility specialist before starting injections.
The good news is that modern IVF protocols have significantly reduced the incidence of severe OHSS. The shift toward using GnRH agonist triggers instead of hCG triggers in high-risk patients, along with freeze-all strategies that delay embryo transfer until hormone levels normalize, has made the worst outcomes much rarer than they were a decade ago. But the risk has not been eliminated, and women going through IVF should know the warning signs: rapid weight gain over a few days, severe abdominal bloating, difficulty breathing, and decreased urination all warrant immediate medical attention.
Effects on Menopause Timing
A question that comes up frequently, and that clinicians sometimes brush off, is whether retrieving large batches of eggs accelerates the depletion of ovarian reserve and pushes menopause earlier. The logic seems intuitive: if you naturally lose one egg per month and IVF harvests 15 at once, aren’t you using up your supply faster? The biology is actually more nuanced than that. In a natural cycle, a whole cohort of follicles begins growing each month, but only one is selected to ovulate. The rest die off regardless. IVF stimulation rescues some of those follicles that would have been lost anyway, so the net impact on long-term egg supply is smaller than it might seem.
That said, at least one study found a statistically significant difference in the age women reached menopause depending on whether they had undergone IVF. Women who had IVF entered menopause at an average age of about 49.8 years, compared to about 50.7 years in the non-IVF group.10PubMed Central. Impact of IVF on the Timing and Symptoms of Menopause The difference of roughly one year is statistically real but not dramatic, and it is unclear how much of that gap is explained by the IVF treatment itself versus the underlying fertility issues that led women to IVF in the first place. Women with diminished ovarian reserve, for instance, are both more likely to pursue IVF and more likely to enter menopause earlier.
An animal study looking at whether ovarian stimulation before chemotherapy harms ovarian reserve found encouraging results: stimulation did not appear to worsen the loss of primordial follicles, the deep reserve of immature eggs that determines how long the ovaries keep functioning.11PubMed. Does controlled ovarian stimulation prior to chemotherapy increase primordial follicle loss and diminish ovarian reserve? An animal study While animal data does not translate directly to humans, this adds to the picture that ovarian stimulation is probably not drastically depleting the egg pool in the way many women fear.
Bone Density and GnRH Agonists
Some IVF protocols use GnRH agonists (drugs like leuprolide) to suppress the body’s own hormone production before stimulation begins. These drugs temporarily create a low-estrogen state similar to menopause, and estrogen is a key hormone for maintaining bone density. In the short term, a couple of weeks of GnRH agonist use during an IVF cycle is unlikely to affect bones in any meaningful way. The concern is for women who use these drugs over longer periods, such as those being treated for endometriosis before IVF or those undergoing multiple back-to-back cycles.
The evidence is mixed and based on relatively small studies. One group of patients with endometriosis treated with GnRH agonists for up to 10 years alongside low-dose hormone add-back therapy showed stable bone density throughout that period. But another small trial found decreased bone density six years after treatment, possibly because the add-back hormone dose was too low to fully protect the bones.12Fertility and Sterility. Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture For most women going through a standard IVF cycle, GnRH agonist exposure lasts only about two weeks, and there is no strong evidence that such brief use has lasting effects on bone health. Women who end up doing many cycles over several years, or who use these drugs for other conditions alongside IVF, should ask about bone monitoring.
Psychological and Emotional Aftermath
The emotional toll of IVF is sometimes treated as a side effect of the “experience” rather than a consequence of the treatment itself, but the hormones genuinely affect mood, and the psychological impact can persist well beyond the treatment period. A Swedish study that followed women 20 to 23 years after IVF found that those who had undergone treatment had higher rates of depressive symptoms and somatization (physical symptoms driven by psychological distress) compared to a reference group. Women who remained childless after IVF were at particular risk for lasting depression and anxiety.13PubMed Central. Mental health in women 20–23 years after IVF treatment: a Swedish cross-sectional study
A systematic review examining the psychological impact of IVF across genders found that anxiety and depression tend to fluctuate during treatment but generally return to baseline after a successful outcome. The lingering effects show up most clearly when treatment fails. Women who went through unsuccessful IVF reported persistent difficulties with self-image, psychological distress, and loss of hope years after treatment ended. Men whose partners went through failed IVF also reported lasting psychological effects, though these tended to manifest differently, centering more on adoption-related concerns and feelings of helplessness.14PubMed Central. The Psychological Impact of In Vitro Fertilization (IVF): A Gender Systematic Review
The hormone injections themselves can exacerbate mood swings, irritability, and emotional volatility during treatment. Whether those hormonal mood effects have truly “long-term” consequences or whether the persistent psychological effects are driven by the stress and grief of the process is hard to separate cleanly. For practical purposes, it does not matter much: if you are going through IVF, the emotional experience is part of the medical experience, and it deserves the same attention as any physical side effect. Mental health support during and after treatment, regardless of outcome, is not a luxury.
Injection Site Reactions That Can Linger
Most women expect some bruising and soreness from IVF injections, and that is usually all they get. But progesterone injections, particularly the intramuscular oil-based shots used for luteal support after embryo transfer, can occasionally cause a more lasting problem. A study of over 5,600 patients who received progesterone injections found that 16 developed panniculitis, an inflammation of the fatty tissue under the skin at the injection site. Women who received more injections were at higher risk. The condition caused visible lumps and discomfort, though all but one of the 16 patients fully recovered with physical therapy.15PubMed Central. Panniculitis caused by progesterone injection can be treated by physical therapy
Panniculitis from progesterone shots is uncommon but not rare enough to dismiss, especially for women doing extended progesterone support through the first trimester. Rotating injection sites, warming the oil before injection, and massaging the area afterward can all reduce the risk. If you notice hard lumps, redness, or persistent pain at an injection site that does not resolve within a week or two, bring it up with your doctor rather than assuming it is normal soreness.
Liver Stress and Rare Complications
Liver complications from IVF medications are rare but have been documented. A case report described a 35-year-old woman who underwent four cycles of controlled ovarian stimulation and later developed severe preeclampsia during pregnancy, which progressed to HELLP syndrome and fatal liver failure.16PubMed Central. Ovarian stimulation and liver dysfunction: Is a clinical relationship possible? A case of hepatic failure after repeated cycles of ovarian stimulation A single case report cannot establish causation, and liver failure during pregnancy has many potential triggers. But the high estrogen levels produced during ovarian stimulation are known to affect liver metabolism, and there is enough biological plausibility that some clinicians monitor liver function more closely in women undergoing repeated stimulation cycles, particularly those with pre-existing liver conditions.
For most women going through one or two IVF cycles, the liver is not a significant concern. But for those who accumulate many cycles over years, or who have a history of liver disease, bile duct problems, or cholestasis in previous pregnancies, it is worth discussing the cumulative hormonal exposure with your doctor.
Separating the Drug Effect From the Infertility Effect
Perhaps the single most important thing to understand about the research on IVF’s long-term effects is that almost all of it struggles with the same fundamental problem: women who undergo IVF are not the same as women who do not. They are older on average, more likely to have hormonal conditions like PCOS or endometriosis, and more likely to have pregnancies complicated by factors related to assisted reproduction (higher rates of twins, more cesarean sections, more preeclampsia). Disentangling the effects of the drugs from the effects of the underlying condition is extraordinarily difficult.
When a study reports that women who had IVF have higher rates of cardiovascular disease or metabolic disorders years later, the IVF medications might be responsible, but so might the PCOS that brought them to IVF, the older age at first pregnancy, or the higher rate of pregnancy complications. The best studies try to control for these factors, but no observational study can do so perfectly.
This is why the breast cancer data is so reassuring: the Dutch cohort study compared IVF women not just to the general population but also to a subfertile comparison group who sought treatment but did not do IVF, and still found no difference.2JAMA. Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer That kind of design, comparing IVF women to infertile women who did not use IVF, is the gold standard for answering whether the drugs themselves are the problem. Unfortunately, most outcomes lack studies this rigorous.
What Ongoing Research Is Watching
Animal research continues to refine our understanding of what ovarian stimulation drugs do at the tissue level. A recent mouse study found that the hormones used for superovulation cause dose-dependent changes in the blood vessel networks surrounding developing follicles, including premature formation of new blood vessels at higher doses.17Reproduction. Superovulation-induced changes in murine ovarian perifollicular angiogenesis Whether these vascular changes have consequences for long-term ovarian health in humans is unknown, but the finding helps explain why higher stimulation doses sometimes lead to poorer-quality eggs and why clinics have been moving toward milder stimulation protocols.
Researchers are also increasingly interested in the epigenetic effects of IVF medications, meaning changes in how genes are expressed rather than changes to the DNA itself. Some early evidence suggests that the hormonal environment during egg maturation might subtly influence gene expression patterns in the resulting embryos. This is a young field with no firm conclusions yet, but it represents the next frontier in understanding whether IVF’s effects extend beyond the woman receiving treatment. For now, the reassuring takeaway is that children conceived through IVF appear to develop normally in the vast majority of cases, even if scientists are still working to understand whether subtle biological differences exist at the molecular level.